Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer von Wu, Yi-Long, Tsuboi, Masahiro, He, Jie, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W, Laktionov, Konstantin, Kim, Sang-We, Kato, Terufumi, Vu, Huu-Vinh, Lu, Shun, Lee, Kye-Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A, Zeng, Lingmin, Hodge, Rachel, Atasoy, Ajlan, Rukazenkov, Yuri, Herbst, Roy S

Volltext

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer von Paz-Ares, Luis, Luft, Alexander, Vicente, David, Tafreshi, Ali, Gümüş, Mahmut, Mazières, Julien, Hermes, Barbara, Çay Şenler, Filiz, Csőszi, Tibor, Fülöp, Andrea, Rodríguez-Cid, Jerónimo, Wilson, Jonathan, Sugawara, Shunichi, Kato, Terufumi, Lee, Ki Hyeong, Cheng, Ying, Novello, Silvia, Halmos, Balazs, Li, Xiaodong, Lubiniecki, Gregory M, Piperdi, Bilal, Kowalski, Dariusz M

Volltext

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer von Spigel, David R, Faivre-Finn, Corinne, Gray, Jhanelle E, Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F, Garassino, Marina C, Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H, Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C, Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J

Volltext

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset von Ohe, Yuichiro, Imamura, Fumio, Nogami, Naoyuki, Okamoto, Isamu, Kurata, Takayasu, Kato, Terufumi, Sugawara, Shunichi, Ramalingam, Suresh S, Uchida, Hirohiko, Hodge, Rachel, Vowler, Sarah L, Walding, Andrew, Nakagawa, Kazuhiko

Volltext

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study von Rudin, Charles M., Awad, Mark M., Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csoszi, Tibor, Cheema, Parneet K., Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J., Luft, Alexander, Gumus, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P., Luo, Yiwen, Ebiana, Victoria, Pietanza, M. Catherine, Kim, Hye Ryun

Volltext

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) von Okada, Morihito, Kijima, Takashi, Aoe, Keisuke, Kato, Terufumi, Fujimoto, Nobukazu, Nakagawa, Kazuhiko, Takeda, Yuichiro, Hida, Toyoaki, Kanai, Kuninobu, Imamura, Fumio, Oizumi, Satoshi, Takahashi, Toshiaki, Takenoyama, Mitsuhiro, Tanaka, Hiroshi, Hirano, Jun, Namba, Yoshinobu, Ohe, Yuichiro

Volltext

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations von Paik, Paul K, Felip, Enriqueta, Veillon, Remi, Sakai, Hiroshi, Cortot, Alexis B, Garassino, Marina C, Mazieres, Julien, Viteri, Santiago, Senellart, Helene, Van Meerbeeck, Jan, Raskin, Jo, Reinmuth, Niels, Conte, Pierfranco, Kowalski, Dariusz, Cho, Byoung Chul, Patel, Jyoti D, Horn, Leora, Griesinger, Frank, Han, Ji-Youn, Kim, Young-Chul, Chang, Gee-Chen, Tsai, Chen-Liang, Yang, James C.-H, Chen, Yuh-Min, Smit, Egbert F, van der Wekken, Anthonie J, Kato, Terufumi, Juraeva, Dilafruz, Stroh, Christopher, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Heymach, John V, Le, Xiuning

Volltext

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations von SEQUIST, Lecia V, YANG, James Chih-Hsin, SU, Wu-Chou, BENNOUNA, Jaafar, KATO, Terufumi, GORBUNOVA, Vera, KI HYEONG LEE, SHAH, Riyaz, MASSEY, Dan, ZAZULINA, Victoria, SHAHIDI, Mehdi, SCHULER, Martin, YAMAMOTO, Nobuyuki, O'BYRNE, Kenneth, HIRSH, Vera, MOK, Tony, GEATER, Sarayut Lucien, ORLOV, Sergey, TSAI, Chun-Ming, BOYER, Michael

Volltext

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, rand... von Seto, Takashi, MD, Kato, Terufumi, MD, Nishio, Makoto, MD, Goto, Koichi, MD, Atagi, Shinji, MD, Hosomi, Yukio, MD, Yamamoto, Noboru, MD, Hida, Toyoaki, MD, Maemondo, Makoto, MD, Nakagawa, Kazuhiko, Prof, Nagase, Seisuke, MD, Okamoto, Isamu, MD, Yamanaka, Takeharu, PhD, Tajima, Kosei, MSc, Harada, Ryosuke, BS, Fukuoka, Masahiro, MD, Yamamoto, Nobuyuki, Prof

Volltext

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phas... von Yang, James Chih-Hsin, Prof, Wu, Yi-Long, Prof, Schuler, Martin, Prof, Sebastian, Martin, MD, Popat, Sanjay, FRCP, Yamamoto, Nobuyuki, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, O'Byrne, Kenneth, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Geater, Sarayut L, MD, Lee, Kye Young, Prof, Tsai, Chun-Ming, Prof, Gorbunova, Vera, Prof, Hirsh, Vera, Prof, Bennouna, Jaafar, Prof, Orlov, Sergey, Prof, Mok, Tony, Prof, Boyer, Michael, Prof, Su, Wu-Chou, Prof, Lee, Ki Hyeong, Prof, Kato, Terufumi, MD, Massey, Dan, MSc, Shahidi, Mehdi, MD, Zazulina, Victoria, MD, Sequist, Lecia V, MD

Volltext

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC von Wu, Yi-Long, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W., Kim, Sang-We, Kato, Terufumi, Laktionov, Konstantin, Vu, Huu Vinh, Wang, Zhijie, Lu, Shun, Lee, Kye Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A., Zeng, Lingmin, Atasoy, Ajlan, Herbst, Roy S., Tsuboi, Masahiro

Volltext

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3 von Kato, Terufumi, Yoshioka, Hiroshige, Okamoto, Isamu, Yokoyama, Akira, Hida, Toyoaki, Seto, Takashi, Kiura, Katsuyuki, Massey, Dan, Seki, Yoko, Yamamoto, Nobuyuki

Volltext

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small... von Papadimitrakopoulou, Vassiliki A., Han, Ji‐Youn, Ahn, Myung‐Ju, Ramalingam, Suresh S., Delmonte, Angelo, Hsia, Te‐Chun, Laskin, Janessa, Kim, Sang‐We, He, Yong, Tsai, Chun‐Ming, Hida, Toyoaki, Maemondo, Makoto, Kato, Terufumi, Jenkins, Suzanne, Patel, Sabina, Huang, Xiangning, Laus, Gianluca, Markovets, Aleksandra, Thress, Kenneth S., Wu, Yi‐Long, Mok, Tony

Volltext

Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease von Kenmotsu, Hirotsugu, Yoh, Kiyotaka, Mori, Keita, Ono, Akira, Baba, Tomohisa, Fujiwara, Yutaka, Yamaguchi, Ou, Ko, Ryo, Okamoto, Hiroaki, Yamamoto, Nobuyuki, Ninomiya, Takashi, Ogura, Takashi, Kato, Terufumi

Volltext

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy von Murakami, Shuji, Usui, Ryou, Nakahara, Yoshiro, Kondo, Tetsuro, Kato, Terufumi, Saito, Haruhiro

Volltext

A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid) von Sugimoto, Akira, Matsumoto, Shingo, Udagawa, Hibiki, Itotani, Ryo, Usui, Yuko, Umemura, Shigeki, Nishino, Kazumi, Nakachi, Ichiro, Kuyama, Shoichi, Daga, Haruko, Hara, Satoshi, Miyamoto, Shingo, Kato, Terufumi, Sakakibara-Konishi, Jun, Tabata, Eriko, Nakagawa, Taku, Kawaguchi, Tomoya, Sakai, Tetsuya, Shibata, Yuji, Izumi, Hiroki, Nosaki, Kaname, Zenke, Yoshitaka, Yoh, Kiyotaka, Goto, Koichi

Volltext

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors von Doi, Toshihiko, Shitara, Kohei, Kojima, Takashi, Kuboki, Yasutoshi, Matsubara, Nobuaki, Bando, Hideaki, Yoh, Kiyotaka, Naito, Yoichi, Hirai, Hiroshi, Kurokawa, Yukinori, Kato, Terufumi, Morizane, Chigusa

Volltext

Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice von Okuda, Ryo, Hagiwara, Eri, Baba, Tomohisa, Kitamura, Hideya, Kato, Terufumi, Ogura, Takashi

Volltext

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial von Akamatsu, Hiroaki, Katakami, Nobuyuki, Okamoto, Isamu, Kato, Terufumi, Kim, Young Hak, Imamura, Fumio, Shinkai, Masaharu, Hodge, Rachel A., Uchida, Hirohiko, Hida, Toyoaki

Volltext

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer von Izumi, Hiroki, Matsumoto, Shingo, Liu, Jie, Tanaka, Kosuke, Mori, Shunta, Hayashi, Kumiko, Kumagai, Shogo, Shibata, Yuji, Hayashida, Takuma, Watanabe, Kana, Fukuhara, Tatsuro, Ikeda, Takaya, Yoh, Kiyotaka, Kato, Terufumi, Nishino, Kazumi, Nakamura, Atsushi, Nakachi, Ichiro, Kuyama, Shoichi, Furuya, Naoki, Sakakibara-Konishi, Jun, Okamoto, Isamu, Taima, Kageaki, Ebi, Noriyuki, Daga, Haruko, Yamasaki, Akira, Kodani, Masahiro, Udagawa, Hibiki, Kirita, Keisuke, Zenke, Yoshitaka, Nosaki, Kaname, Sugiyama, Eri, Sakai, Tetsuya, Nakai, Tokiko, Ishii, Genichiro, Niho, Seiji, Ohtsu, Atsushi, Kobayashi, Susumu S., Goto, Koichi

Volltext